Board of Directors of Obagi Medical Products, Inc. Receives Unsolicited Acquisition Proposal from Merz Pharma

LONG BEACH, Calif.–(BUSINESS WIRE)– On April 2, 2012, Obagi Medical Products, Inc. (NAS: OMPI) (the “Company” or “Obagi”) announced that the Obagi Board of Directors had received an unsolicited letter from Merz Pharma offering $22 per share cash to acquire the Company, and the Obagi Board of Directors will evaluate Merz Pharma‘s offer and the merger terms consistent with its fiduciary and legal duties. The Obagi Board of Directors realizes that time is of the essence in this matter.

About Obagi Medical Products, Inc.

Obagi Medical Products is a specialty pharmaceutical company that develops, markets and sells, and is a leading provider of, proprietary topical aesthetic and therapeutic prescription-strength skin care systems in the physician-dispensed market. Using its Penetrating Therapeutics™ technologies, Obagi Medical‘s products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including premature aging, photodamage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, sun damage, rosacea, and soft tissue deficits, such as fine lines and wrinkles. Obagi Medical‘s portfolio, which includes cosmetic, over-the-counter and prescription products, including 4% hydroquinone, is sold and promoted only through physician offices and requires education by a physician on proper use. The history of Obagi’s skin care product introductions is as follows: Obagi Nu-Derm^®, Obagi-C^® Rx (a prescription-strength vitamin C and hydroquinone system), Obagi^® Professional-C (a line of highly stable vitamin C serums), Obagi Condition & Enhance^® for use with cosmetic procedures to enhance patient outcomes and satisfaction, ObagiELASTIderm^® Eye Products and ObagiCLENZIderm^® M.D. acne therapeutic systems, a formulation of ObagiCLENZIderm M.D. Systems for normal to dry skin, and ObagiELASTIderm Décolletage System, ObagiRosaclear^® System, ObagiELASTILash^® Eyelash Solution, Obagi Blue Peel RADIANCE^®, Nu-Derm^® Sun Shield SPF 50 and Obagi Hydrate™. Visit www.obagi.com for information.

Penetrating Therapeutics and Obagi Hydrate are trademarks, and Obagi, the Obagi logo, Blue Peel RADIANCE, Condition & Enhance, ELASTIderm, ELASTILash, Nu-Derm, Obagi-C, ObagiCLENZIderm and Rosaclear are registered trademarks, of Obagi Medical Products, Inc. and/or its affiliates in the United States and certain other countries.

Notice to Investors

On March 26, 2013, Obagi Medical Products, Inc. filed a solicitation/recommendation statement with respect …read more
Source: FULL ARTICLE at DailyFinance